Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Entasis Therapeutics is raising $24,999,999.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Manos Perros played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Entasis Therapeutics

Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sciences, Pivotal bioVenture Partners, Sofinnova, TPG Biotechnology Partners and Eventide Gilead Fund, to advance our pipeline of breakthrough anti-infective products.

To learn more about Entasis Therapeutics, visit http://www.entasistx.com/

Contact:
Manos Perros, Chief Executive Officer
781-810-0120
https://www.linkedin.com/in/manos-perros-9142142/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved